• Publications
  • Influence
Modeling immunotherapy of the tumor – immune interaction
  • Denise Kirschner, J. Panetta
  • Biology, Medicine
  • Journal of mathematical biology
  • 1 September 1998
The dynamics between tumor cells, immune-effector cells, and IL-2 are illustrated through mathematical modeling and the effects of adoptive cellular immunotherapy are explored to explain both short tumor oscillations in tumor sizes as well as long-term tumor relapse. Expand
Mrp4 Confers Resistance to Topotecan and Protects the Brain from Chemotherapy
The topotecan resistance of cells overexpressingMrp4 and the polarized expression of Mrp4 in the choroid plexus and brain capillary endothelial cells indicate that Mr p4 has a dual role in protecting the brain from cytotoxins and suggest that the therapeutic efficacy of central nervous system-directed drugs that are Mrp3 substrates may be improved by developing Mrp 4 inhibitors. Expand
Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.
A genome-wide interrogation identified inherited variations in a plausible, yet heretofore low-priority candidate gene, SLCO1B1, as important determinants of methotrexate's pharmacokinetics and clinical effects. Expand
Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo.
Results were extended to human orthologues using engineered cell lines to show that gefitinib inhibited the efflux of BCRP and MDR1 substrates and restored vincristine sensitivity in MDR 1-expressing cells. Expand
Optimal Control Applied to Cell-Cycle-Specific Cancer Chemotherapy
This work designs the control functional to maximize both the bone marrow mass and the dose over the treatment interval, and describes the optimal control in terms of the solutions to the optimality system, which is the state system coupled with the adjoint system. Expand
Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia.
Overall, older age, lower albumin, higher lipid levels, and dexamethasone exposure were associated with osteonecrosis and may be linked by inherited genomic variation. Expand
Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia.
MTX-related clinical neurotoxicity is transient, and most patients can receive subsequent MTX without recurrence of acute or subacute symptoms, and all symptomatic patients and one in five asymptomatic patients develop leukoencephalopathy that can persist until the end of therapy. Expand
A mathematical model of breast and ovarian cancer treated with paclitaxel.
  • J. Panetta
  • Medicine
  • Mathematical biosciences
  • 1 December 1997
A mathematical model that describes the effects of cell-cycle-specific drugs on cancer and normal tissue is developed and some acceptable treatment strategies are discussed in terms of treatment period, drug-infusion time, and proliferative fraction of cancer mass. Expand
Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia.
It is shown that in mouse models of BCR-ABL1 leukemia, Ikzf1 and Arf alterations synergistically promote the development of an aggressive lymphoid leukemia, and retinoid receptor agonists potentiated the activity of dasatinib in mouse and human B CR-ABl1 ALL, providing an additional therapeutic option in IKZF1-mutated ALL. Expand
Genome-wide study of methotrexate clearance replicates SLCO1B1.
Validation of this variant with 5 different treatment regimens of methotrexate solidifies the robustness of this pharmacogenomic determinant of metotrexate clearance. Expand